Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

However, in the third trial, the difference in fasting plasma glucose levels between patients receiving vildagliptin 50 mg bid plus pioglitazone 45 mg qd and those receiving placebo plus pioglitazone was ∼10 mg/dL, and did not reach statistical significance ( Garber et al 2007 ).

also in 111,027 other papers